AHRQ lab-developed test assessment
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality posts a final 1tech assessment on the "Quality, Regulation and Clinical Utility of Laboratory-developed Tests" on its website June 22. The report, largely unchanged from a draft document issued last August, was requested by CMS' Coverage and Analysis Group (2"The Gray Sheet" Aug. 24, 2009). The assessment concludes that establishing the quality of lab-developed tests is challenging and the lack of clinical validity or utility assessment is cause for concern. In particular, "given the dynamic nature of the molecular testing area, the assessments of the quality, regulation or utility of [lab-developed molecular tests] need to be frequently updated." FDA is seeking to finalize a comprehensive framework for oversight of lab-developed tests, with a public meeting on the matter scheduled for July 19-20 (3"The Gray Sheet" June 21, 2010)
You may also be interested in...
FDA Aims To Finalize Framework For Lab-Developed Tests In Near Term
FDA could have a final framework in place for overseeing a greatly expanded range of laboratory test services within months of a public meeting scheduled for July, according to agency officials
Guaranteeing Quality Of Lab-Developed Molecular Tests Is Difficult - AHRQ
A new report on laboratory-developed molecular tests lends another voice to arguments favoring enhanced oversight of these non-FDA-regulated products and services
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.